コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 brentuximab vedotin and 65 to physician's choice), with 128 analysed in the intention-to-treat population (64 in each gro
2 as the time from randomisation until death from any cause), analysed in the intention-to-treat population.
3 al response at 12 weeks (SVR12) after treatment completion, analysed in the intention-to-treat population.
4 unstable angina, and hospital admission for heart failure, analysed in the intention-to-treat population (all participan
6 n Test (WMFT) at the end of the 2 week intervention period, analysed in the intention-to-treat population.
7 were the safety and tolerability of the treatment regimen, analysed in the intention-to-treat population.
8 TEC-3 trial were overall survival and failure-free survival analysed in the intention-to-treat population.
10 radiographic progression-free survival and overall survival analysed in the intention-to-treat population.
12 dpoints reported here are 5-year progression-free survival (analysed in the intention-to-treat population) and disease-fr
13 points were overall survival and progression-free survival, analysed in the intention-to-treat population (n=675), with d
14 The primary endpoint was overall survival, analysed in the intention-to-treat population, using a two-st
16 ophil percentage from baseline to 12 weeks after treatment, analysed in the intention-to-treat population.
18 orced expiratory volume in 1 s (FEV1) on day 169, which was analysed in the intention-to-treat population.
22 ant difference in disease-free survival between groups when analysed in the intention-to-treat population.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。